Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down - Should You Sell?

Key Points

• Daiichi Sankyo shares experienced a gap down opening, falling from a previous close of $24.50 to open at $23.50, and last traded at $23.86.
• Nomura Securities upgraded Daiichi Sankyo to a “strong-buy” rating, contributing to an overall average rating of “Strong Buy” from analysts.
• The company has a market capitalization of $45.18 billion and maintains a low debt-to-equity ratio of 0.06, indicating strong financial health.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report)'s share price gapped down before the market opened on Friday . The stock had previously closed at $24.50, but opened at $23.50. Daiichi Sankyo shares last traded at $23.86, with a volume of 4,980 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Nomura Securities upgraded shares of Daiichi Sankyo to a "strong-buy" rating in a research note on Friday, June 6th. One analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, Daiichi Sankyo currently has an average rating of "Strong Buy".

Daiichi Sankyo Price Performance

The stock has a market capitalization of $45.18 billion and a price-to-earnings ratio of 23.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.85 and a current ratio of 2.53. The company has a fifty day simple moving average of $23.92 and a two-hundred day simple moving average of $24.13.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.